Effect of combined oral proteases and flavonoid treatment in subjects at risk of Type 1 diabetes: Letter: Original Observation

Diabetic Medicine

Volumn 26, Issue 12, 2009, Pages 1309-1310

  Kempf, K ^a,b   Manzo, G ^a   Hanifi Moghaddam, P ^a   Kappler, S ^a   Seissler, J ^a,c   Jaeger, C ^d   Boehm, B ^e   Roden, M ^a,f   Kolb, H ^a   Martin, S ^a,b   Schloot, N C ^a,f  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BROMELAIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; QUERCETIN; RUTOSIDE; TRYPSIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; MAJOR CLINICAL STUDY; MULTICENTER STUDY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BROMELAINS; CHILD; CHILD, PRESCHOOL; CYTOKINES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FLAVONOIDS; HUMANS; INCIDENCE; PEPTIDE HYDROLASES; PLACEBOS; PROSPECTIVE STUDIES; RISK; RUTIN; TRYPSIN; YOUNG ADULT;

EID: 70549106273     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02879.x     Document Type: Letter

References (6)

1. Wiest-Ladenburger U, Richter W, Boehm B. Protease treatment delays diabetes onset in NOD mice. Int J Tissue React 1997 13 : 89 93.
2. Roep BO, van den Engel NK, van Halteren AG, Duinkerken G, Martin S. Modulation of autoimmunity to beta-cell antigens by proteases. Diabetologia 2002 45 : 686 692.
3. Hale LP, Haynes BF. Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. J Immunol 1992 149 : 3809 3816.
4. Bamigboye AA, Smyth R. Interventions for varicose veins and leg oedema in pregnancy. Cochrane Database Syst Rev 2007 1 : CD001066.
5. Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003 52 : 1137 1142.
6. Schloot NC, Hanifi-Moghaddam P, Aabenhus-Andersen N, Alizadeh BZ, Saha MT, Knip M et al. Association of immune mediators at diagnosis of Type 1 diabetes with later clinical remission. Diabet Med 2007 24 : 512 520.